Fruquintinib

11 registered clinical trials studyying Fruquintinib — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in F NCT07257653	Zhejiang University	Phase 2
Recruiting	A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cance NCT07136077	M.D. Anderson Cancer Center	Phase 2
Not Yet Recruiting	MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G/GEJ Adenocarcinoma NCT07144995	Sun Yat-sen University	—
Not Yet Recruiting	Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer NCT06888037	Ruijin Hospital	Phase 2
Not Yet Recruiting	Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer NCT06871527	Sixth Affiliated Hospital, Sun Yat-sen University	Phase 1 / Phase 2
Recruiting	Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanc NCT07334431	Henan Cancer Hospital	Phase 1 / Phase 2
Unknown	Fruquintinib in the Cross-line Treatment of Refractory mCRC NCT06099314	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	—
Unknown	TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer NCT05993702	China Medical University, China	—
Unknown	A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patie NCT06169202	China Medical University, China	—
Recruiting	Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC NCT06427005	Meng Qiu	Phase 2
Unknown	Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma NCT05122091	Guangxi Medical University	Phase 2